Renalytix plc

Renalytix plc is an in vitro diagnostics company focused on managing kidney disease through artificial intelligence-enabled prognostic tools. The company develops and provides diagnostic services designed to assess the risk of progressive kidney function decline in adults with type 2 diabetes and early-stage chronic kidney disease. Its core offering, kidneyintelX.dkd, combines blood biomarkers with clinical algorithms to assist clinicians in identifying individuals who require early medical intervention before major organ damage occurs. The company markets its diagnostic testing services primarily to healthcare providers, primary care physicians, and clinical networks across the healthcare sector.

The company operates certified clinical laboratories in Salt Lake City, Utah, and St. Petersburg, Florida, alongside additional facilities in New York. Its commercial activities focus primarily on regional markets in the United States, including New York, Florida, and Texas. Renalytix plc is organized under the laws of England and Wales and maintains its principal executive offices in London, United Kingdom.

Summary of the business section of Renalytix's latest annual report, written by StockData.